MabThera.com is a comprehensive resource for healthcare professionals outside the US who are interested in MabThera and the treatment of lymphoma. This site provides detailed information on MabThera, monoclonal antibody therapy, management strategies for non-Hodgkin's lymphoma (NHL) and clinical trials.
Read European Summary of Product Characteristics (ESPC) and Brief Prescribing Information on Mabthera.
Safety information
MabThera effectively eradicates CD20+ cells in lymphoma patients by several distinct mechanisms.
Mechanism of action
MabThera is a chimeric murine anti-CD20 antibody. Learn about the properties and production of this highly active therapy.
Active ingredient
Access the Brief Prescribing Information for MabThera in NHL
MabThera has demonstrated clinically proven efficacy in treating indolent and aggressive NHL.
Traditionally CLL has been considered an incurable disease and short-term responses were considered the best markers of therapy success.
MabThera maintenance therapy prolongs response to induction chemotherapy and is approved for patients with relapsed/refractory follicular lymphoma.